作者: Zangrillo, Alberto ; Di Prima, Ambra L ; Celinska-Spodar, Malgorzata ; Agracheva, Nataliya ; Taddeo, Daiana ; Pappalardo, Federico ; Lembo, Rosalba ; Crivellari, Martina ; Landoni, Giovanni

PURPOSETo determine whether protein C zymogen (protein C concentrates or human protein C) improves clinically relevant outcomes in adult patients with severe sepsis and septic shock.METHODSThis is a randomized, double-blind, placebo-controlled, parallel-group trial that from September 2012 to June 2014 enrolled adult patients with severe sepsis or septic shock and high risk of death and of bleeding (e.g., APACHE II greater than 25, extracorporeal membrane oxygenation or disseminated intravascular coagulopathy). All patients completed their follow-up 90 days after randomization and data were analyzed according to the intention-to-treat principle. Follow-up was performed at 30 and 90 days after randomization. The primary endpoint was a composite outcome of prolonged intensive care unit (ICU) stay and/or 30-day mortality. Secondary endpoints included mortality.RESULTSThe study was stopped early in a situation of futility for the composite outcome of prolonged ICU stay and/or 30-day mortality that was 79 % (15 patients) in the protein C zymogen group and 67 % (12 patients) in the placebo group (p = 0.40) and for a concomitant safety issue: ICU mortality was 79 % (15 patients) in the protein C zymogen group vs 39 % (7 patients) in the placebo group (p = 0.020), and 30-day mortality was 68 vs 39 % (p = 0.072).CONCLUSIONProtein C zymogen did not improve clinically relevant outcomes in severe sepsis and septic shock adult patients. Given its high cost and the potential increase in mortality, the use of this drug in adult patients should be discouraged.

2013-05-01·Haemophilia2区 · 医学

Paediatric presentation and outcome of congenital protein C deficiency in Japan

2区 · 医学

Article

作者: Kanegane, H. ; Shirahata, A. ; Kayamori, Y. ; Ochiai, M. ; Hara, T. ; Ikenoue, T. ; Kinjo, T. ; Ishimura, M. ; Yamamoto, J. ; Urata, M. ; Doi, T. ; Ohga, S. ; Kang, D. ; Suenobu, S.‐I.

SummarySevere heritable protein C (PC) deficiency is quite rare, although heterozygous

PROC

mutation is the second leading cause of genetic predisposition to thrombosis in Japanese adults. The aim of the study was to search the optimal management, the paediatric onset and outcomes of PC deficiency were characterized in Japan. The genetic study, postmarketing survey of activated PC (aPC) concentrate (Anact®C) and intensive review in Japan for 20 years enabled the analysis of the disease onset, genotype, treatment and prognosis. Symptomatic PC deficiency was determined in 27 Japanese children. All but two patients presented within 16 days after birth (three prenatal and six neonatal onsets). Postnatal‐onset cases had normal growth at full‐term delivery. Of the 27 patients, 19 suffered intracranial thrombosis or haemorrhage (ICTH) (three foetal hydrocephalies), 16 developed purpura fulminans (PF) and 10 had both at the first presentation. ICTH preceded PF in both affected cases. Low PC activities of 18 mothers and/or 12 fathers indicated 20 inherited PC deficiencies (2 homozygotes, 11 compound heterozygotes and 7 heterozygotes) and seven unidentified causes of PC deficiency. Nine of 11 patients studied had PROC mutations. Four unrelated patients (50%) carried PC nagoya (1362delG). No PC‐deficient parents had experienced thromboembolism. Of the 18 patients with aPC therapy, two died and eight evaluable survivors had neurological sequelae. This first comprehensive study of paediatric PC deficiency suggested that perinatal ICTH was the major presentation, occurring earlier than neonatal PF. PC nagoya was prevalent in paediatric, but not adult, patients in Japan. Early maternal screening and optimal PC therapy are required for newborns at risk of PC deficiency.

2012-10-01·Thrombosis Research3区 · 医学

Diversity of Human Plasma Protein C Inhibitor

3区 · 医学

Article

作者: Saito, Akio

Protein C inhibitor was purified from human plasma by use of a dermatan sulfate or heparin column, followed by hydroxyapatite, gel filtration and ion exchange columns. A dimer of protein C inhibitor was detected by SDS-PAGE under reducing conditions, in addition to two forms of monomer species. One of the monomers, 52-kDa PCI, formed a stable complex with activated protein C, urokinase, plasma and tissue kallikrein, but the dimer species and 48-kDa PCI were inactive. When the monomer and dimer forms of protein C inhibitor were applied to 2D-PAGE, more than 20 spots were observed by Western blot analysis and were confirmed to be protein C inhibitor by MALDI-TOF mass spectrometry. The heterogeneity of the protein C inhibitor species was not due to glycosylation or phosphorylation.

项与干燥浓缩人活化蛋白C(KM Biologics KK) 相关的新闻（医药）

2023-06-13

·药闻康策

收藏！2023年医保目录调整盘点

☝ 点击上方一键预约 ☝ 最新最热的医药健康新闻政策2023年6月9日晚间，国家医保局发布了《2023年国家基本医疗保险、工伤保险和生育保险药品目录调整工作方案》及相关文件公开征求意见，于6月15日前公开征求意见。规则的变与不变纵览征求意见稿，总体规则与2022年相似：①创新药节点卡在今年6月30日（独家认定时间节点）；②儿童药和罕见病药不限制在2018年1月1日以后。微调的细节也有：01不再纳入最新版《新型冠状病毒肺炎诊疗方案》药品，只是符合2018年1月1日至2023年6月30日获批的新通用名的新冠药可申报；02强化对相关企业的监督，建立诚信档案，对于企业在目录调整过程中弄虚作假，违法违规等行为，一经查实，视情节与目录调整和申报资格挂钩。在申报指南方面，医保局有更细化的规定：01因转产、再注册等原因，单纯更改通用名的药品，不属于时间节点内新通用名药品；02无需再邮寄纸质申报材料；03申报内容的经济性信息不再包含医保基金支出预算，但经济信息需包含2021年1月1日至2023年6月30日大陆地区药品销售金额（含全部规格），当前价格费用情况，预计未来三年销量和对医保基金的影响等；04公平性方面，明确要求说明是否能够弥补药品目录短板，临床管理难度和其他相关星期。目录外药品还需要提供价格费用等信息。符合《基本医疗保险用药管理暂行办法》第七条、第八条规定，且具备以下情形之一的目录外药品，可以申报参加2023年药品目录调整。一2018年1月1日至2023年6月30日（含，下同）期间，经国家药监部门批准上市的新通用名药品。符合本条件的新冠治疗用药，可按程序申报。201801-202306批准上市的部分药品（暂未进医保）数据来源：NMPA、CDE、药渡整理：10号茶馆二2018年1月1日至2023年6月30日期间，经国家药监部门批准，适应症或功能主治发生重大变化，且针对此次变更获得药品批准证明文件的药品。三纳入《国家基本药物目录（2018年版）》的药品。四纳入鼓励仿制药品目录或鼓励研发申报儿童药品清单，且于2023年6月30日前，经国家药监部门批准上市的药品。五2023年6月30日前，罕见病治疗药品。第四批鼓励研发申报儿童药品建议清单序号药品名称英文名称剂型规格 1 Vosoritide Vosoritide 注射剂1.2mg注射剂0.56mg注射剂0.4mg2喷他脒Pentamidine Isethionate粉针剂300mg3硝唑尼特Nitazoxanide混悬剂100mg/5ml4吉妥珠单抗/吉妥单抗Gemtuzumab/Gemtuzumab Ozogamicin注射剂4.5 mg5AnifrolumabAnifrolumab注射剂2ml:0.3g6克罗拉滨/氯法拉滨Clofarabine注射剂1mg/ml7博舒替尼Bosutinib片剂0.1g8奈莫利珠单抗Nemolizumab注射剂60mg9BezlotoxumabBezlotoxumab注射剂1ml:25mg10GivosiranGivosiran注射剂0.189g11加奈索酮Ganaxolone混悬剂1ml:50mg12雷美替胺Ramelteon片剂8mg13匹莫齐特Pimozide片剂1mg14Avalglucosidase alfaAvalglucosidase alfa注射剂0.1g15 苯丙氨酸氨裂解酶 Pegvaliase 注射剂2.5mg注射剂20mg16TeplizumabTeplizumab注射剂2ml:2mg17苯丁酸甘油酯Glycerol Phenylbutyrate溶液剂1.1g/ml18Olipudase alfaOlipudase alfa注射剂20mg19卡培立肽Carperitide粉针剂1mg20非诺多泮Fenoldopam注射剂10mg/ml21纳多洛尔Nadolol片剂40mg22 Turoctocog alfa pegolTuroctocog alfa pegol注射剂500IU注射剂1000IU23左甲状腺素钠Levothyroxine口服溶液剂5ml:0.15mg24胰高血糖素Glucagon鼻用散剂3mg25芬戈莫德Fingolimod口腔崩解片0.25mg26米诺环素Minocycline外用泡沫剂4%27托氟沙星Tosufloxacin颗粒剂1g:0.15g 28 哌甲酯 Methylphenidate 缓释胶囊5mg缓释胶囊10mg缓释胶囊60mg29格列本脲Glibenclamide混悬剂1ml:0.6mg第三批鼓励研发申报儿童药品清单序号药品通用名剂型规格1地西泮口服溶液剂1mg/ml, 100ml2利多卡因喷雾剂10mg/喷, 50ml3螺内酯口服溶液剂1mg/ml, 5ml4西地那非口服混悬剂10mg/ml, 112ml5依那普利口服溶液剂1mg/ml, 150ml6索他洛尔口服溶液剂1mg/ml7双嘧达莫口服混悬剂10mg/ml8蛋白C注射剂500 IU9氯吡格雷口服混悬剂1mg/ml, 50ml10XIII因子注射剂250 IU11四氢生物蝶呤片剂20mg、100mg12无水甜菜碱散剂180g13他克莫司颗粒剂0.2mg、1mg14阿那白滞素注射剂100mg/0.67ml15乙琥胺糖浆剂100ml:5g16舒噻嗪片剂100mg17盐酸右美托咪定鼻用喷雾剂1.0g:200μg18阿司匹林口服溶液剂（或口服混悬剂、口服乳剂）5mg/ml19后叶加压素注射剂20IU/ml20Ataluren颗粒剂125mg21睾酮注射剂100mg/ml, 10ml22伏立康唑口服混悬剂40mg/ml23磺胺甲噁唑+甲氧苄啶口服混悬剂200mg/ml （磺胺甲噁唑）；40mg/ml（甲氧苄啶），5ml24吗替麦考酚酯口服混悬剂200mg/ml, 175ml25盐酸曲恩汀胶囊剂250mg26吡斯的明注射剂1mg/ml27缬沙坦口服溶液剂3mg/ml, 160ml28奎尼丁口服溶液剂（或口服混悬剂、口服乳剂）1mg/ml29苯丁酸钠片剂500mg30甲硝唑口服溶液剂40mg/ml, 5ml31胺碘酮口服混悬剂1mg/ml, 100ml32苯乙酸钠+苯甲酸钠注射剂100mg/ml（苯乙酸钠）；100mg/ml（苯甲酸钠），50ml33曲普瑞林注射剂11.25mg34奈拉滨注射剂250mg第二批鼓励研发申报儿童药品清单序号药品通用名剂型规格1胍法辛缓释片2mg2环磷酰胺片剂25mg3埃索美拉唑颗粒剂10mg4万古霉素口服液体制剂125mg5乙胺丁醇口服溶液剂25mg/ml6吡嗪酰胺口服溶液剂30mg/ml7盐酸二甲双胍口服溶液剂100mg/ml8波生坦片剂20mg9多佐胺+噻吗洛尔滴眼剂噻吗洛尔5mg/ml，多佐胺20mg/ml10氯巴占片剂10mg11甲基苄肼胶囊剂50mg12抗D免疫球蛋白注射用无菌粉末500IU13氨己烯酸散剂500mg14艾司洛尔片剂50mg15氯氮平口服混悬剂50mg/ml16美司钠片剂200mg17奥美拉唑口服溶液剂2mg/ml18美沙拉嗪栓剂500mg19去氨加压素口服溶液剂360ug/ml鼻用喷雾剂10μg/揿20硫唑嘌呤注射用无菌粉末50mg21阿托品滴眼剂0.10%22红霉素口服溶液剂40mg/ml23巴氯芬口服溶液剂1mg/ml24氨氯地平口服混悬剂1mg/ml25骨化三醇口服溶液剂1μg/ml26羟基脲片剂100 mg27磺胺甲噁唑+甲氧苄啶注射液磺胺甲噁唑80mg/ml，甲氧苄啶16mg/ml28氟氢可的松口服液体制剂适宜规格29吸入一氧化氮吸入气体适宜规格30布洛芬赖氨酸盐注射液2ml:10mg/ml31依库珠单抗注射液10mg/ml32制霉菌素糊剂（口腔黏膜用）适宜规格33阿替卡因注射用无菌粉末（低渗透压）13.3mg34生物素片剂5mg35维拉苷酶α注射用无菌粉末400IU36睾内酯片剂50mg37褪黑素缓释片2mg38二巯基丁二钠片剂100mg39活性炭口服混悬剂208mg/ml第一批鼓励研发申报儿童药品清单品种剂型规格苯海索口服酏剂0.4mg/ml苯妥英钠注射剂50mg/ml（5ml）地高辛注射剂0.05mg/ml（1ml）地西泮灌肠剂1mg/ml呋塞米口服溶液4mg/ml氟哌啶醇口服溶液2mg/ml卡托普利口服溶液5mg/ml劳拉西泮注射剂2mg/ml（1ml）氯硝西泮口服溶液0.1mg/ml咪达唑仑口腔黏膜溶液5mg/ml(1ml)尼莫地平口服溶液3mg/ml普萘洛尔口服溶液1mg/ml肾上腺素注射剂0.1mg/ml(1ml)碳酸氢钠注射剂1.4%(100ml)水合氯醛口服溶液、口服混悬液或灌肠液二氮嗪口服溶液50mg/ml（30ml）长春碱（长春花碱）注射剂1mg苯丙氨酸氮芥（马法兰）注射剂50mg巯嘌呤口服混悬液20mg/ml华法林口服混悬液1mg/ml熊去氧胆酸口服混悬液50mg/ml左乙拉西坦注射剂500mg/5ml异烟肼糖浆剂10mg/ml柳氮磺吡啶口服混悬液50mg/ml利福平口服混悬液20mg/ml重组人甲状旁腺激素注射剂20ug胰高血糖素注射剂1mg多粘菌素E口服制剂胰岛素样生长因子-1注射剂10mg双氢睾酮注射剂20mg双氢睾酮凝胶80g促皮质素（ACTH）注射剂40IU，80IU（来源: GBIHealth 作者:GBI）有需要2023年医保目录调整相关产品表格汇总（Excel版），请扫描下方二维码添加客服微信咨询，申请加入药闻康策高端会员群获取。药闻康策新媒体矩阵微信公众号点击下方一键关注【免责声明】1.“药闻康策”部分文章信息来源于网络转载是出于传递更多信息之目的，并不意味着赞同其观点或证实其内容的真实性。如对内容有疑议，请及时与我司联系。2.“药闻康策”致力于提供合理、准确、完整的资讯信息，但不保证信息的合理性、准确性和完整性，且不对因信息的不合理、不准确或遗漏导致的任何损失或损害承担责任。3.“药闻康策”所有信息仅供参考，不做任何商业交易或医疗服务的根据，如自行使用“药闻康策”内容发生偏差，我司不承担任何责任，包括但不限于法律责任，赔偿责任。欢迎转发分享、点赞、点在看

上市批准

2023-05-26

·药闻康策

事关新版基药调整！第四批鼓励研发申报儿童药品建议清单公示

点击上方一键预约最新最热的医药健康新闻政策2023年05月26日，国家卫健委药物政策与基本药物制度司公示了第四批鼓励研发申报儿童药品建议清单，公示5个工作日。关于第四批鼓励研发申报儿童药品建议清单的公示为进一步落实原国家卫生计生委等6部门《关于保障儿童用药的若干意见》要求，丰富儿童适用药品的品种、剂型和规格，满足儿科临床用药需求，2023年，国家卫生健康委、科技部、工业和信息化部、国家医保局和国家药品监管局继续紧密围绕我国儿童疾病谱以及相关企业研发生产能力，组织临床、药学、研发、注册等有关专家结合中国大陆境内尚未注册上市且临床急需的儿童用药现状，基于循证原则筛选论证，提出了《第四批鼓励研发申报儿童药品建议清单》。现予以公示，公示5个工作日。第四批鼓励研发申报儿童药品建议清单序号药品名称英文名称剂型规格 1 Vosoritide Vosoritide 注射剂1.2mg注射剂0.56mg注射剂0.4mg2喷他脒Pentamidine Isethionate粉针剂300mg3硝唑尼特Nitazoxanide混悬剂100mg/5ml4吉妥珠单抗/吉妥单抗Gemtuzumab/Gemtuzumab Ozogamicin注射剂4.5 mg5AnifrolumabAnifrolumab注射剂2ml:0.3g6克罗拉滨/氯法拉滨Clofarabine注射剂1mg/ml7博舒替尼Bosutinib片剂0.1g8奈莫利珠单抗Nemolizumab注射剂60mg9BezlotoxumabBezlotoxumab注射剂1ml:25mg10GivosiranGivosiran注射剂0.189g11加奈索酮Ganaxolone混悬剂1ml:50mg12雷美替胺Ramelteon片剂8mg13匹莫齐特Pimozide片剂1mg14Avalglucosidase alfaAvalglucosidase alfa注射剂0.1g15 苯丙氨酸氨裂解酶 Pegvaliase 注射剂2.5mg注射剂20mg16TeplizumabTeplizumab注射剂2ml:2mg17苯丁酸甘油酯Glycerol Phenylbutyrate溶液剂1.1g/ml18Olipudase alfaOlipudase alfa注射剂20mg19卡培立肽Carperitide粉针剂1mg20非诺多泮Fenoldopam注射剂10mg/ml21纳多洛尔Nadolol片剂40mg22 Turoctocog alfa pegolTuroctocog alfa pegol注射剂500IU注射剂1000IU23左甲状腺素钠Levothyroxine口服溶液剂5ml:0.15mg24胰高血糖素Glucagon鼻用散剂3mg25芬戈莫德Fingolimod口腔崩解片0.25mg26米诺环素Minocycline外用泡沫剂4%27托氟沙星Tosufloxacin颗粒剂1g:0.15g 28 哌甲酯 Methylphenidate 缓释胶囊5mg缓释胶囊10mg缓释胶囊60mg29格列本脲Glibenclamide混悬剂1ml:0.6mg第三批鼓励研发申报儿童药品清单序号药品通用名剂型规格1地西泮口服溶液剂1mg/ml, 100ml2利多卡因喷雾剂10mg/喷, 50ml3螺内酯口服溶液剂1mg/ml, 5ml4西地那非口服混悬剂10mg/ml, 112ml5依那普利口服溶液剂1mg/ml, 150ml6索他洛尔口服溶液剂1mg/ml7双嘧达莫口服混悬剂10mg/ml8蛋白C注射剂500 IU9氯吡格雷口服混悬剂1mg/ml, 50ml10XIII因子注射剂250 IU11四氢生物蝶呤片剂20mg、100mg12无水甜菜碱散剂180g13他克莫司颗粒剂0.2mg、1mg14阿那白滞素注射剂100mg/0.67ml15乙琥胺糖浆剂100ml:5g16舒噻嗪片剂100mg17盐酸右美托咪定鼻用喷雾剂1.0g:200μg18阿司匹林口服溶液剂（或口服混悬剂、口服乳剂）5mg/ml19后叶加压素注射剂20IU/ml20Ataluren颗粒剂125mg21睾酮注射剂100mg/ml, 10ml22伏立康唑口服混悬剂40mg/ml23磺胺甲噁唑+甲氧苄啶口服混悬剂200mg/ml （磺胺甲噁唑）；40mg/ml（甲氧苄啶），5ml24吗替麦考酚酯口服混悬剂200mg/ml, 175ml25盐酸曲恩汀胶囊剂250mg26吡斯的明注射剂1mg/ml27缬沙坦口服溶液剂3mg/ml, 160ml28奎尼丁口服溶液剂（或口服混悬剂、口服乳剂）1mg/ml29苯丁酸钠片剂500mg30甲硝唑口服溶液剂40mg/ml, 5ml31胺碘酮口服混悬剂1mg/ml, 100ml32苯乙酸钠+苯甲酸钠注射剂100mg/ml（苯乙酸钠）；100mg/ml（苯甲酸钠），50ml33曲普瑞林注射剂11.25mg34奈拉滨注射剂250mg第二批鼓励研发申报儿童药品清单序号药品通用名剂型规格1胍法辛缓释片2mg2环磷酰胺片剂25mg3埃索美拉唑颗粒剂10mg4万古霉素口服液体制剂125mg5乙胺丁醇口服溶液剂25mg/ml6吡嗪酰胺口服溶液剂30mg/ml7盐酸二甲双胍口服溶液剂100mg/ml8波生坦片剂20mg9多佐胺+噻吗洛尔滴眼剂噻吗洛尔5mg/ml，多佐胺20mg/ml10氯巴占片剂10mg11甲基苄肼胶囊剂50mg12抗D免疫球蛋白注射用无菌粉末500IU13氨己烯酸散剂500mg14艾司洛尔片剂50mg15氯氮平口服混悬剂50mg/ml16美司钠片剂200mg17奥美拉唑口服溶液剂2mg/ml18美沙拉嗪栓剂500mg19去氨加压素口服溶液剂360ug/ml鼻用喷雾剂10μg/揿20硫唑嘌呤注射用无菌粉末50mg21阿托品滴眼剂0.10%22红霉素口服溶液剂40mg/ml23巴氯芬口服溶液剂1mg/ml24氨氯地平口服混悬剂1mg/ml25骨化三醇口服溶液剂1μg/ml26羟基脲片剂100 mg27磺胺甲噁唑+甲氧苄啶注射液磺胺甲噁唑80mg/ml，甲氧苄啶16mg/ml28氟氢可的松口服液体制剂适宜规格29吸入一氧化氮吸入气体适宜规格30布洛芬赖氨酸盐注射液2ml:10mg/ml31依库珠单抗注射液10mg/ml32制霉菌素糊剂（口腔黏膜用）适宜规格33阿替卡因注射用无菌粉末（低渗透压）13.3mg34生物素片剂5mg35维拉苷酶α注射用无菌粉末400IU36睾内酯片剂50mg37褪黑素缓释片2mg38二巯基丁二钠片剂100mg39活性炭口服混悬剂208mg/ml（备注：口服液体制剂包括：口服溶液剂、口服混悬剂、口服乳剂、口服滴剂 )首批鼓励研发申报儿童药品清单品种剂型规格苯海索口服酏剂0.4mg/ml苯妥英钠注射剂50mg/ml（5ml）地高辛注射剂0.05mg/ml（1ml）地西泮灌肠剂1mg/ml呋塞米口服溶液4mg/ml氟哌啶醇口服溶液2mg/ml卡托普利口服溶液5mg/ml劳拉西泮注射剂2mg/ml（1ml）氯硝西泮口服溶液0.1mg/ml咪达唑仑口腔黏膜溶液5mg/ml(1ml)尼莫地平口服溶液3mg/ml普萘洛尔口服溶液1mg/ml肾上腺素注射剂0.1mg/ml(1ml)碳酸氢钠注射剂1.4%(100ml)水合氯醛口服溶液、口服混悬液或灌肠液二氮嗪口服溶液50mg/ml（30ml）长春碱（长春花碱）注射剂1mg苯丙氨酸氮芥（马法兰）注射剂50mg巯嘌呤口服混悬液20mg/ml华法林口服混悬液1mg/ml熊去氧胆酸口服混悬液50mg/ml左乙拉西坦注射剂500mg/5ml异烟肼糖浆剂10mg/ml柳氮磺吡啶口服混悬液50mg/ml利福平口服混悬液20mg/ml重组人甲状旁腺激素注射剂20ug胰高血糖素注射剂1mg多粘菌素E口服制剂胰岛素样生长因子-1注射剂10mg双氢睾酮注射剂20mg双氢睾酮凝胶80g促皮质素（ACTH）注射剂40IU，80IU( 注：药品适应症应包括儿科适应症或具备儿童用法用量）来源：国家卫健委药物政策与基本药物制度司药闻康策新媒体矩阵微信公众号点击下方一键关注【免责声明】1.“药闻康策”部分文章信息来源于网络转载是出于传递更多信息之目的，并不意味着赞同其观点或证实其内容的真实性。如对内容有疑议，请及时与我司联系。2.“药闻康策”致力于提供合理、准确、完整的资讯信息，但不保证信息的合理性、准确性和完整性，且不对因信息的不合理、不准确或遗漏导致的任何损失或损害承担责任。3.“药闻康策”所有信息仅供参考，不做任何商业交易或医疗服务的根据，如自行使用“药闻康策”内容发生偏差，我司不承担任何责任，包括但不限于法律责任，赔偿责任。欢迎转发分享、点赞、点在看

临床结果申请上市

100 项与干燥浓缩人活化蛋白C(KM Biologics KK) 相关的药物交易

登录后查看更多信息